Novo Nordisk CEO Lars Fruergaard Jørgensen is stepping down amid declining share prices and increased competition in the obesity drug market. The company's share price has fallen over 50% since mid-2024 following disappointing trial results for new treatments. While the company maintains its current business plans, the CEO's departure reflects challenges faced in the market. A replacement is being sought, and Lars Rebien Sørensen will join the board as an observer.

Prepared by Christopher Adams and reviewed by editorial team.